Engineered immune cells take on deadly brain tumors
Disease control
Not yet recruiting
This early-phase trial tests a new treatment for people with recurrent malignant glioma, an aggressive brain cancer. The therapy uses the patient's own immune cells, modified to target the cancer and boost the immune response. The study aims to check safety and see if it can slow…
Phase: PHASE1 • Sponsor: Ming Yang • Aim: Disease control
Last updated May 06, 2026 16:15 UTC